Premium
Effects of Daidzein and Vincristine on Medulloblastoma Cell Proliferation
Author(s) -
Stout Jessica Mae,
Sierman Audrey R,
Cheatwood Joseph Laton
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.979.21
Subject(s) - daidzein , genistein , vincristine , medulloblastoma , chemotherapy , medicine , oncology , soy isoflavones , immune system , bioavailability , cell growth , pharmacology , cancer research , immunology , chemistry , cyclophosphamide , biochemistry
Medulloblastoma – the most common type of childhood brain cancer – is a malignant tumor of the cerebellum that can spread throughout the central nervous system. Currently, the primary treatment for MB patients is chemotherapy, but its use is limited due to its negative side effects, which include cognitive and neurological dysfunctions, growth impairment of the brain, and immune system compromise. Previous studies with the isoflavone genistein determined that a diet high in soy could potentially reduce the amount of chemotherapy drugs necessary to treat MB, which would consequently reduce the risk of harmful side effects while maintaining or improving disease control. Unlike genistein, daidzein – another key soy isoflavone with high bioavailability – has not been studied. Therefore, we sought to detail the effects of vincristine coupled with daidzein on MB cell lines. For this, HTB‐186 cells were treated with daidzein and varied concentrations of vincristine. Cells in all treatment groups were incubated for 1 week. After the study period, the viable cells in each group were enumerated via a dye exclusion assay. Grant Funding Source : Saluki Scholars Research Opportunity